On June 30, 2025, Leerink Partners analyst Jonathan Chang announced adjustments to his price target for Zai Lab (ZLAB, Financial), raising it to $75.00 USD from the previous target of $73.00 USD. This update reflects a 2.74% increase in the target price, signifying a positive outlook on the company's stock performance.
The stock rating for Zai Lab (ZLAB, Financial) remains unchanged at "Outperform," indicating continued confidence in the company's potential for above-average market returns. The recent adjustment highlights investor optimism and the expectation of growth in Zai Lab's financial performance.
Investors should note that ZLAB is currently listed on the NASDAQ exchange. The latest price target adjustment by Leerink Partners reinforces the belief in Zai Lab's potential to deliver strong returns and maintain its competitive position in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for Zai Lab Ltd (ZLAB, Financial) is $54.22 with a high estimate of $73.00 and a low estimate of $38.20. The average target implies an upside of 55.86% from the current price of $34.79. More detailed estimate data can be found on the Zai Lab Ltd (ZLAB) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Zai Lab Ltd's (ZLAB, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Zai Lab Ltd (ZLAB, Financial) in one year is $63.17, suggesting a upside of 81.58% from the current price of $34.79. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Zai Lab Ltd (ZLAB) Summary page.
